Aclaris Therapeutics (NASDAQ:ACRS) Price Target & New Coverage by Guggenheim
Guggenheim analyst has started coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a $53.0 target and Buy rating. The target suggests a potential upside of 110.23 % from company’s close price.
Despite the new coverage NASDAQ:ACRS is at the moment trading -2.86% lower at $19.01 as of 6:04 PM New York time. Aclaris Therapeutics shares have [From2] 0% over the past 200 days, while the Standard & Poor’s 500 index has increased 6.00% during the same time period.
Out of 3 brokers covering Aclaris Therapeutics, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $30 and the lowest is $20 according to Thomson/First Call. The 12-month mean target is $26.33, which means upside potential of 38.51% over the current price.
Aclaris Therapeutics (NASDAQ:ACRS) Profile
Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Aclaris Therapeutics (NASDAQ:ACRS) traded down -2.86% on 9 February, hitting $19.01. A total of 555,388 shares of the company’s stock traded hands. This is up from average of 370,905 shares. Aclaris Therapeutics has a 52 week low of $18.46 and a 52 week high of $33.25. The company has a market cap of $553.92 million and a P/E ratio of 0.
Get the latest Aclaris Therapeutics (NASDAQ:ACRS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Guggenheim Has Started Coverage on Aclaris Therapeutics (NASDAQ:ACRS) with Buy and with $53.0 Target appeared first on Octafinance.